tiprankstipranks
Trending News
More News >
Balaji Amines Limited (IN:BALAMINES)
:BALAMINES
India Market
Advertisement

Balaji Amines Limited (BALAMINES) AI Stock Analysis

Compare
4 Followers

Top Page

IN:BALAMINES

Balaji Amines Limited

(BALAMINES)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
₹1,330.00
▲(15.37% Upside)
Balaji Amines' overall stock score is primarily influenced by its strong financial performance, which is offset by bearish technical indicators and a relatively high valuation. The company's financial stability is a positive, but technical analysis suggests caution due to negative market momentum.
Positive Factors
Business Model Strength
The company's focus on specialty chemicals, especially amines, provides a strong business model with diversified applications across multiple industries, ensuring consistent demand.
Balance Sheet Health
A robust balance sheet with low leverage enhances financial stability, providing flexibility for future investments and growth opportunities.
Cash Generation Ability
Strong cash generation supports ongoing operations and investment in growth initiatives, contributing to long-term sustainability.
Negative Factors
Revenue Growth Challenges
A decline in revenue growth indicates potential market challenges or increased competition, which could impact future profitability and market position.
Earnings Pressure
Negative EPS growth suggests earnings pressure, possibly due to market conditions or operational inefficiencies, affecting investor confidence and financial performance.
Market Conditions
Contraction in revenue and net income highlights potential market headwinds or competitive pressures, necessitating strategic adjustments to maintain growth.

Balaji Amines Limited (BALAMINES) vs. iShares MSCI India ETF (INDA)

Balaji Amines Limited Business Overview & Revenue Model

Company DescriptionBalaji Amines Limited (BALAMINES) is a leading manufacturer of specialty chemicals, primarily focusing on amines and their derivatives. The company operates in various sectors, including pharmaceuticals, agrochemicals, and personal care products, providing essential raw materials that cater to diverse industrial applications. BALAMINES offers a wide range of products, including methylamines, ethylamines, and other specialty amines, which are integral to the production of various chemical formulations.
How the Company Makes MoneyBalaji Amines generates revenue through the production and sale of its specialty chemicals, particularly amines and their derivatives. The company has established a strong revenue model based on a diverse customer base spanning multiple industries, including pharmaceuticals, agrochemicals, and personal care. Key revenue streams include the sale of high-demand products such as methylamines and ethylamines, which are utilized in numerous applications from drug manufacturing to agricultural chemicals. Additionally, BALAMINES benefits from long-term partnerships with major players in its target sectors, ensuring consistent demand for its products. The company also focuses on research and development to innovate and expand its product offerings, further enhancing its market position and revenue potential.

Balaji Amines Limited Financial Statement Overview

Summary
Balaji Amines demonstrates strong financial health with a stable balance sheet and consistent cash flow generation. Despite revenue pressures, the company maintains profitability, indicating good operational efficiency. However, addressing revenue challenges is crucial for long-term growth.
Income Statement
76
Positive
Balaji Amines has shown resilience in its income statement despite revenue fluctuations. The Gross Profit Margin and Net Profit Margin have been reasonably stable, reflecting effective cost management. However, the recent contraction in revenue and net income suggests challenges in market conditions or competition.
Balance Sheet
82
Very Positive
The balance sheet is strong, with a low Debt-to-Equity Ratio indicating conservative financial leverage. The equity ratio is robust, showcasing a solid capital structure. However, the company should watch for any increase in liabilities that could affect its financial stability.
Cash Flow
79
Positive
Cash flow metrics reveal effective cash management, with positive Free Cash Flow indicating the ability to sustain operations and investments. While the Operating Cash Flow to Net Income ratio is healthy, the company must focus on improving cash flow growth to support future expansions.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.71B13.97B16.08B23.38B23.20B13.11B
Gross Profit5.59B4.88B3.50B8.39B8.57B5.39B
EBITDA2.55B2.65B3.53B6.24B6.36B3.79B
Net Income1.52B1.58B2.05B3.26B3.68B2.38B
Balance Sheet
Total Assets0.0022.52B21.46B19.63B18.75B13.10B
Cash, Cash Equivalents and Short-Term Investments3.50B3.50B3.31B3.09B515.37M173.23M
Total Debt0.00110.27M196.97M575.74M1.01B1.27B
Total Liabilities-20.18B2.34B2.53B2.65B5.60B4.00B
Stockholders Equity20.18B18.45B17.22B15.54B12.50B8.94B
Cash Flow
Free Cash Flow0.00874.82M704.14M2.62B842.07M-221.07M
Operating Cash Flow0.002.73B3.34B3.82B2.32B1.10B
Investing Cash Flow0.00-1.61B-1.64B-1.86B-1.47B-615.89M
Financing Cash Flow0.00-447.73M-749.66M-812.33M-565.13M-374.51M

Balaji Amines Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1152.85
Price Trends
50DMA
1365.37
Negative
100DMA
1497.68
Negative
200DMA
1443.01
Negative
Market Momentum
MACD
-66.35
Positive
RSI
28.68
Positive
STOCH
35.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Negative. The current price of 1152.85 is below the 20-day moving average (MA) of 1287.17, below the 50-day MA of 1365.37, and below the 200-day MA of 1443.01, indicating a bearish trend. The MACD of -66.35 indicates Positive momentum. The RSI at 28.68 is Positive, neither overbought nor oversold. The STOCH value of 35.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹32.92B24.080.08%15.47%-1.72%
66
Neutral
₹122.24B78.690.06%69.32%113.55%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
₹45.54B29.910.95%-10.76%-27.70%
61
Neutral
₹93.53B51.340.60%3.95%8.28%
51
Neutral
₹38.85B115.480.09%8.44%-35.59%
47
Neutral
₹8.41B138.911.14%-22.10%-85.56%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BALAMINES
Balaji Amines Limited
1,152.85
-898.02
-43.79%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,677.95
-280.98
-14.34%
IN:ANURAS
Anupam Rasayan India Ltd.
1,220.20
487.88
66.62%
IN:FAIRCHEMOR
Fairchem Organics Ltd
653.40
-189.54
-22.49%
IN:NEOGEN
Neogen Chemicals Ltd.
1,125.05
-966.82
-46.22%
IN:ROSSARI
Rossari Biotech Ltd
601.00
-214.73
-26.32%

Balaji Amines Limited Corporate Events

Balaji Amines Reschedules Q2FY26 Earnings Call
Nov 11, 2025

Balaji Amines Limited has announced a change in the schedule for its investor conference call to discuss the Q2 and H1FY26 financial results. Originally planned for 4:00 PM IST, the call has been rescheduled to 12:30 PM IST on the same day, November 12, 2025. This adjustment reflects the company’s proactive approach to engaging with stakeholders and ensuring timely communication of its financial performance.

Balaji Amines Clarifies Misleading Article on Chemical Production
Oct 14, 2025

Balaji Amines Limited has issued a clarification regarding a defamatory article published in the Economic Times, which falsely accused the company of producing pharmaceutical-grade chemicals without a license. The company refutes these claims, stating that they only manufacture technical and food grade Propylene Glycol and have not supplied any pharmaceutical-grade products. Balaji Amines emphasizes their commitment to transparency and compliance with regulations, noting that there is no ongoing investigation by Indian authorities as suggested in the article.

Balaji Amines Limited Submits Compliance Certificate for Q3 2025
Oct 4, 2025

Balaji Amines Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that the securities received for dematerialization have been processed, with the depositories’ names updated in the company’s records within the required timeframe, ensuring compliance with regulatory standards.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 14, 2025